Retatrutide Phase 3 Program: 2026 TRIUMPH & TRANSCEND Trial Results

#### Extended Follow-Up (104 Weeks, BMI ≥35 Cohort)

In the 104-week extension for participants with baseline BMI ≥35, retatrutide 12 mg achieved 30.3% mean weight loss (~85 lbs)—the first Phase 3 obesity trial to sustain weight loss exceeding 30%. This threshold approaches outcomes observed after bariatric surgery, positioning retatrutide peptide as a significant pharmacological advancement in obesity treatment.

#### Secondary Cardiometabolic Outcomes

Retatrutide showed significant improvements in cardiovascular risk factors:

• Triglycerides: substantial reductions from baseline
• Systolic blood pressure: significant improvements
• High-sensitivity C-reactive protein (hsCRP): reduced inflammation marker
• LDL cholesterol: favorable changes across treatment arms

TRIUMPH-4: Knee Osteoarthritis Comorbidity Trial

#### Methodology and Design

TRIUMPH-4 was the first large-scale Phase 3 trial of any GLP-1-class agent to evaluate a disease-specific clinical outcome in knee osteoarthritis. The trial randomized participants with obesity and moderate-to-severe knee osteoarthritis to retatrutide or placebo, with pain measured via the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score.

#### Key Findings (December 2025)

• **Retatrutide 9 mg WOMAC pain reduction**: 4.0 points (approximately 75.8% improvement from baseline)
• **Placebo WOMAC pain reduction**: 2.1 points
• **Pain-free achievement**: 14.1% on retatrutide 9 mg versus 4.2% on placebo
• **Mean weight loss**: 28.7% at trial completion

The 75.8% pain reduction substantially exceeds the expected benefit from weight loss alone in osteoarthritis populations, suggesting a direct anti-inflammatory and disease-modifying contribution from the GLP-1, GIP, and glucagon receptor activation. This finding is particularly significant as it demonstrates that retatrutide's triple-agonist mechanism may confer benefits beyond metabolic control.

TRANSCEND-T2D-1: Type 2 Diabetes Monotherapy Trial

#### Study Design

TRANSCEND-T2D-1 (NCT06354660) was a 40-week, Phase 3, randomized, double-blind, placebo-controlled trial published simultaneously in *The Lancet* (2026). The study enrolled 537 adults with type 2 diabetes and inadequate glycemic control despite diet and exercise alone. Participants were treatment-naïve (no anti-diabetes medications for ≥90 days prior) and insulin-naïve (except for gestational diabetes). Baseline A1C ranged from 7.0% to 9.5%, and BMI ≥23 kg/m². Participants were randomized 1:1:1:1 to retatrutide 4 mg, 9 mg, 12 mg, or placebo, with stepwise dose escalation every four weeks.

#### Glycemic Control Outcomes

All retatrutide doses demonstrated superior A1C reduction compared to placebo at week 40:

• **A1C reduction**: 1.7–2.0% (19–22 mmol/mol) across 4 mg, 9 mg, and 12 mg doses
• **A1C <7.0% achievement**: 82–89% of retatrutide-treated participants
• **A1C ≤6.5% achievement**: Significant proportions across all doses
• **A1C <5.7% achievement**: Significant proportions (near-normoglycemic targets)

#### Weight Loss in Type 2 Diabetes

Remarkably, TRANSCEND-T2D-1 demonstrated weight loss beyond that observed in similar studies of GLP-1 agonist monotherapy:

• **Mean weight loss**: 11.5–16.8% (average 36.6 lbs at highest dose)
• **Composite endpoint achievement**: >50% of participants on retatrutide reached both A1C ≤6.5% AND ≥10% weight reduction

This dual efficacy addresses a significant unmet need: prior GLP-1 and GIP monotherapy trials typically achieve glycemic control *or* substantial weight loss, but rarely both simultaneously to this magnitude.

#### Cardiometabolic Improvements

Beyond glucose and weight, retatrutide improved:

• LDL cholesterol ("bad" cholesterol)
• Triglycerides (blood fats associated with cardiovascular risk)
• Blood pressure

These findings suggest that retatrutide's triple-agonist mechanism may provide broader cardiometabolic benefit than dual-agonist therapies in early-stage type 2 diabetes.

Obstructive Sleep Apnea: Secondary TRIUMPH-1 Analysis

A secondary analysis of TRIUMPH-1 in participants with moderate-to-severe obstructive sleep apnea (OSA) revealed:

• **Apnea-Hypopnea Index (AHI) reduction**: 60.6% improvement (from baseline 58.6 events/hour to approximately 23 events/hour)
• **Clinical significance**: This reduction moves participants from moderate-to-severe OSA into mild OSA territory
• **Mechanism**: Weight loss (primary driver) combined with potential direct anti-inflammatory effects of triple-agonist activation

This finding is noteworthy because OSA is a common, underdiagnosed comorbidity in obesity and type 2 diabetes, and pharmacological improvement in AHI represents a novel outcome for incretin-based therapies.

Safety and Tolerability Profile

#### Adverse Event Summary

Across TRIUMPH-1, TRIUMPH-4, and TRANSCEND-T2D-1, the safety profile was consistent with the established GLP-1 receptor agonist class:

• **Most common adverse events**: Gastrointestinal (nausea, vomiting, diarrhea, constipation)
• **Severity**: Generally mild to moderate; most resolved with continued dosing or dose optimization
• **Discontinuation rates**: Dose-dependent, up to 11.3% on 12 mg dose
• **No new safety signals**: Adverse event profile aligned with semaglutide and tirzepatide

#### Retatrutide-Specific Signal: Dysesthesia

A dose-dependent dysesthesia signal (abnormal skin sensation) was observed, occurring in up to 12.5% of participants on the 12 mg dose. This represents a potential class-specific effect requiring further monitoring in ongoing trials and post-marketing surveillance. The mechanism and clinical significance remain under investigation.

#### Weight Loss Plateau Assessment

Importantly, participants in TRIUMPH-1 had not reached a weight loss plateau by week 80, and TRANSCEND-T2D-1 participants had not plateaued by week 40. This suggests that retatrutide peptide may continue to drive weight loss and metabolic improvements beyond the trial observation periods, though longer-term data are required to establish true plateau kinetics.

Clinical Implications and Unmet Needs

Retatrutide addresses several significant gaps in obesity and type 2 diabetes pharmacotherapy:

1. **Magnitude of weight loss**: The 28–30% sustained reduction approaches bariatric surgery outcomes, offering a non-invasive alternative for severe obesity.

1. **Dual endpoint efficacy**: Simultaneous achievement of robust glycemic control and substantial weight loss in type 2 diabetes monotherapy is unprecedented in Phase 3 trials.

1. **Comorbidity management**: Direct improvements in knee osteoarthritis pain and obstructive sleep apnea suggest that triple-agonist activation may address obesity-related complications beyond metabolic control.

1. **Early intervention**: Efficacy in treatment-naïve type 2 diabetes patients (TRANSCEND-T2D-1) positions retatrutide as a potential first-line agent, potentially delaying or preventing progression to insulin therapy.

Regulatory Pathway and Timeline

As of June 2026, Eli Lilly has completed three pivotal Phase 3 readouts (TRIUMPH-1, TRIUMPH-4, TRANSCEND-T2D-1) and anticipates additional results from TRIUMPH-2, TRIUMPH-3, TRIUMPH-5, TRIUMPH-6, and a second TRANSCEND diabetes trial through 2026 and 2027. FDA approval is expected as early as late 2026 or early 2027 if remaining 2026 readouts are positive. New Drug Application (NDA) filing may occur in Q4 2026.

Distinction Between Mechanism and Outcomes

While retatrutide is sometimes referred to as a peptide in research contexts (given its amino acid composition and receptor-agonist mechanism), it is technically a synthetic polypeptide pharmaceutical. This distinction is important for researchers evaluating its pharmacology relative to other peptide-based therapies such as semaglutide, tesamorelin peptide, or sermorelin peptide therapy, which operate via distinct hormonal axes.

Conclusion

The 2026 Phase 3 results for retatrutide represent a significant advancement in obesity and type 2 diabetes pharmacotherapy. The combination of unprecedented sustained weight loss (30.3% in the BMI ≥35 cohort), robust glycemic control (A1C reductions of 1.7–2.0%), and meaningful improvements in obesity-related comorbidities (knee osteoarthritis pain reduction of 75.8%, AHI reduction of 60.6%) positions retatrutide as a potential paradigm shift in metabolic disease management. The consistent safety profile, while including a novel dysesthesia signal requiring monitoring, supports the feasibility of this triple-agonist approach. Pending positive results from the remaining Phase 3 trials, retatrutide may become available as a first-line therapy for moderate-to-severe obesity and early-stage type 2 diabetes as early as late 2026 or 2027.